We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NICE Endorses Pfizer and Eli Lilly Cancer Drugs

NICE Endorses Pfizer and Eli Lilly Cancer Drugs

August 25, 2016

The UK’s drug pricing watchdog has recommended reimbursement for Eli Lilly’s lung cancer drug Alimta and Pfizer’s leukemia therapy Bosulif at discounted prices.

The products had previously been available under the National Health Service’s Cancer Drugs Fund, but underwent reappraisal after the cancer fund experienced restructuring and fell under the purview of UK’s National Institute for Health and Care Excellence.

NICE noted that it only endorsed the drugs after the companies lowered the drugs for an undisclosed amount. The discounts rendered the treatments cost-effective, NICE said.

Bosulif is recommended when other treatment options for chronic myeloid leukemia become ineffective. An annual course of treatment without discounts costs roughly $59,275.

Alimta is backed as an initial treatment for patients with advanced non-small-cell lung cancer. The average cost of eight treatment cycles is $15,242.

View today's stories

Pharmaceuticals Regulatory Affairs Commercial Operations

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

  • abbott-logo.gif

    Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

  • 100Bills_flatmoney.gif

    In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing